HC Wainwright & Co. Maintains Buy on Alpine Immune Sciences, Raises Price Target to $17
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Joseph Pantginis maintains a 'Buy' rating on Alpine Immune Sciences (NASDAQ:ALPN) and raises the price target from $11 to $17.
August 15, 2023 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alpine Immune Sciences' price target has been raised from $11 to $17 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Alpine Immune Sciences. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100